Description
Sotorasib is prescribed to adults with non-small cell lung cancer (NSCLC) that has metastasized or is inoperable after prior treatments. It belongs to the class of drugs known as KRAS inhibitors, working to disrupt the abnormal protein driving cancer cell multiplication, ultimately slowing or halting cancer spread.